- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00209170
Depression-Diabetes Mechanisms: Urban African Americans
연구 개요
상세 설명
To determine the psychobehavioral and neurohormonal mechanisms of effective treatment, the investigator will conduct a randomized, double-blind, placebo-controlled trial in patients with major depression, who will receive either: (i) computer-based cognitive behavioral therapy (CBT) program entitled "Beating the Blues" + placebo, or (ii) computer-based cognitive behavioral therapy (CBT) program entitled "Beating the Blues" + the SSRI antidepressant escitalopram. The investigator will assess (a) glycemic control (levels of glycated hemoglobin (HbA1c)), in relation to (b) adherence (keeping scheduled return appointments, diet, exercise, and glucose monitoring), (c) depressive symptoms (neurocognitive and neurobehavioral symptoms determined by self- and observer-rated scales), and (d) the four pathways of neurometabolic function.
Study visits will occur once a month for 6 months. Should patients report severe environmental stressors (such as marital conflict, loss of family member or job, being exposed to trauma), patients will be offered an intensification of their contact with study personnel, e.g. weekly contact by phone or "in-person" visits to see study personnel at the Grady Diabetes Clinic.
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
Georgia
-
Atlanta, Georgia, 미국, 30303
- Grady Hospital Diabetes Clinic
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Subjects must be English-speaking
- African American
- Have type 2 diabetes per American Diabetes Association criteria
- Patient's receiving care at Grady Hospital
Exclusion Criteria:
- Severely depressed (Hamilton Depression Rating Scale (HAM-D) ≥ 34
- Non - English speaking
- Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.
currently meet Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for:
- Bipolar Disorder
- Schizophrenia or any Psychotic Disorder
- Obsessive Compulsive Disorder
- Mental Retardation or any Pervasive Developmental Disorder or Cognitive Disorder.
- Personality Disorder of sufficient severity to interfere with their participation in the study
- Psychotic features or with history of Psychotic Disorder, as defined by DSM-IV
- Suicide risk, or have made serious suicide attempt in the past year
- Substance Abuse or Dependence (other than nicotine) during the six months preceding the first dose of double blind study medication
- Any malignancy (other than excised basal cell carcinoma), or any clinically significant hematological, endocrine, cardiovascular (including any rhythm disorder), renal, hepatic, gastrointestinal, or neurological disease. History of syndrome of inappropriate anti-diuretic hormone secretion.
- Diabetes due to: glucagonoma, pheochromocytoma or other endocrine neoplasm, drug induced diabetes, gestational diabetes, or those with established genetic defects of beta cell function.
- Medical conditions that will interfere with the HbA1c assay or if hospitalization is likely within two months (sickle cell anemia, hypersplenism)
- A history of diabetic ketoacidosis episode during the 6 months preceding the first dose of double-blind study medication.
- Uncontrolled diabetes as judged by the investigator defined as blood glucose greater than 400 on last two visits or patients whom suffered from diabetic ketoacidosis in the last month or have had 2 episodes in the last year.
- Autonomic or peripheral neuropathy that requires treatment
- At the first follow-up visit - Patients with systolic blood pressure greater than 180 mm Hg or less than 90 mm Hg or diastolic blood pressure greater than 105 mm Hg or less than 50 mm Hg
- Treatment with a depot neuroleptic during the last 6 months
- Patients who have been treated with any neuroleptic, antidepressant, or anxiolytic medication
- Participation in an investigational drug study within 1 month prior to study entry or who have received treatment with an investigational drug within 1 month or five half-lives, whichever is longer.
- Previous investigational study of escitalopram or previously treated with escitalopram in a dose and duration sufficient for therapeutic trial.
- History of hypersensitivity reaction to escitalopram or citalopram.
- Electroconvulsive therapy during the past 3 months
- Initiation or termination of behavior therapy or psychotherapy in the 3 months.
- Positive urine screening for alcohol, illicit drugs, or any prohibited medication
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Beating the Blues CBT + Escitalopram
Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with the selective serotonin reuptake inhibitor (SSRI) antidepressant, escitalopram (10 mg taken orally once or twice daily) for 6 months
|
Beating the Blues is a computerized cognitive behavioral therapy.
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant.
It's a 10 mg pill taken once or twice daily for 6 months.
다른 이름들:
|
활성 비교기: Beating the Blues CBT + Placebo
Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with placebo (taken orally one to two tablets daily) for 6 months
|
Beating the Blues is a computerized cognitive behavioral therapy.
A sugar pill taken as one to two tablets daily for 6 months.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week 24
기간: Baseline, week 24
|
The 21-item HDRS measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 60, where higher scores indicate greater severity. The HDRS at week 24 was compared to the baseline HDRS and each participant's response was calculated using the below table: No Response = < 25% change in Depression Rating Scale Score Partial Responder =< 50% to >25% change in Depression Rating Scale Score Responder = 50% or greater change in Depression Rating Scale Score |
Baseline, week 24
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Dominique L Musselman, MD, MS, Emory University
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IRB00001092
- R01MH069254-03 (미국 NIH 보조금/계약)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Beating the Blues에 대한 임상 시험
-
Edwards Lifesciences종료됨
-
Edwards LifesciencesICON plc종료됨
-
Memorial Sloan Kettering Cancer Center종료됨
-
University of Nebraska LincolnUniversity of Nebraska완전한
-
VA Office of Research and Development완전한
-
University of New BrunswickHorizon Health Network; Universite de Moncton; New Brunswick Health Research Foundation; Fitness...완전한
-
Asian Institute of Gastroenterology, IndiaOvesco Endoscopy AG아직 모집하지 않음
-
Medical College of Wisconsin종료됨